Target Name: CCN3
NCBI ID: G4856
Other Name(s): nephro blastoma-overexpressed gene protein homolog | IGFBP9 | NOV protein | Nephro blastoma-overexpressed gene protein homolog | IGFBP-9 | IBP-9 | NOVh | insulin-like growth factor-binding protein 9 | NOVH | Protein NOV homolog | IGF-binding protein 9 | CCN family member 3 | Cellular communication network factor 3 | NOV | protein NOV homolog | nephroblastoma-overexpressed gene protein homolog | Insulin-like growth factor-binding protein 9 | NovH | nephroblastoma overexpressed | cellular communication network factor 3 | CCN3_HUMAN

CCN3: A Potential Drug Target and Biomarker for Nephro Blastoma

Blastoma is a type of cancer that arises from the epithelial tissue lining the various body organs, including the kidneys. It is a rare and aggressive form of cancer, with a high mortality rate due to its tendency to infiltrate the surrounding healthy tissue and the limited availability of effective treatments. Despite its aggressive nature, blastoma is a relatively good-tasting cancer, which may present a more favorable prognosis compared to some other forms of cancer. However, the poor prognosis is primarily due to the limited treatment options available for blastoma, which are often ineffective and can have severe side effects.

One potential solution to this problem is the use of drugs that can inhibit the activity of CCN3, a gene protein that is overexpressed in blastoma cells. CCN3 is a transmembrane protein that is involved in various signaling pathways, including cell adhesion, migration, and invasion. It has been shown to be involved in the development and progression of blastoma, and may be a useful target for cancer therapies.

In recent years, researchers have been increasingly interested in using drugs that can inhibit the activity of CCN3 to treat blastoma. This is because CCN3 has been shown to play a role in the development of resistance to chemotherapy in blastoma, making it a potential target for cancer therapies. Additionally, the overexpression of CCN3 has been shown to be associated with poor prognosis in blastoma patients, which may make it an attractive target for cancer therapies.

One potential drug that can inhibit the activity of CCN3 is a small molecule inhibitor called NXJ-7830. This compound was synthesized by the company NuVasive and has been shown to be an effective inhibitor of CCN3 in blastoma cells. NXJ-7830 works by binding to the G protein-coupled receptor (GPCR) CCN3, which is involved in various signaling pathways, including cell adhesion and migration. By binding to CCN3, NXJ-7830 can inhibit the activity of CCN3 and prevent blastoma cells from undergoing the processes that lead to their aggressive behavior.

In addition to its potential as a drug, NXJ-7830 has also been shown to be a potential biomarker for blastoma. This is because the levels of NXJ-7830 have been shown to be elevated in blastoma cells, which may indicate that they are more sensitive to the inhibitor. Additionally, the levels of NXJ-7830 have been shown to be correlated with the size and number of blastoma tumors, which may indicate that it can be used as a marker for the effectiveness of a potential cancer therapy.

Another potential drug that may be able to inhibit the activity of CCN3 in blastoma cells is a monoclonal antibody called A33. This antibody is designed to bind to a specific epitope (a region of the protein that is unique to each cell) on the surface of CCN3, and has been shown to be effective in inhibiting the activity of CCN3 in various cell types, including blastoma cells. A33 has been shown to be particularly effective in inhibiting the activity of CCN3 in blastoma cells, and may be a promising target for cancer therapies.

In conclusion, CCN3 is a gene protein that is overexpressed in blastoma cells and has been shown to play a role in the development and progression of this aggressive form of cancer. The use of drugs that can inhibit the activity of CCN3, such as NXJ-7830, may be a promising solution to the limited treatment options available for blastoma. Additionally, NXJ-7830 has also been shown to be a potential biomarker for blastoma, which may indicate that it has the potential to

Protein Name: Cellular Communication Network Factor 3

Functions: Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival (PubMed:15181016, PubMed:15611078, PubMed:12695522, PubMed:21344378, PubMed:12050162). Acts by binding to integrins or membrane receptors such as NOTCH1 (PubMed:12695522, PubMed:21344378, PubMed:15611078). Essential regulator of hematopoietic stem and progenitor cell function (PubMed:17463287). Inhibits myogenic differentiation through the activation of Notch-signaling pathway (PubMed:12050162). Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling (PubMed:20139355). Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival (PubMed:12695522). Also plays a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts (PubMed:15611078). Involved in bone regeneration as a negative regulator (By similarity). Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification (PubMed:21871891). Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion (By similarity). Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway (PubMed:21063504). Contributes to the control and coordination of inflammatory processes in atherosclerosis (By similarity). Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement (PubMed:21871891)

More Common Targets

CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207